Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Dasatinib + Quercetin (Senolytic Stack) | Semaglutide | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing). | Research indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily. |
| Timing | Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion. | SC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications. |
| Cycle Duration | Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess). | Long-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials). |
| Evidence Level | moderate_human | Strong (FDA-approved) |
Dasatinib is a multi-kinase inhibitor (targeting SRC, ABL, c-KIT, PDGFR, and ephrin receptors) originally developed for chronic myeloid leukemia. Quercetin is a natural flavonoid that inhibits PI3K, serpine/PAI-2, BCL-xL, and other anti-apoptotic pathways. Together, they constitute a senolytic combination that selectively induces apoptosis in senescent cells by disabling the senescent cell anti-apoptotic pathways (SCAPs) that allow damaged, non-dividing cells to resist programmed cell death. Senescent cells accumulate with aging and secrete the SASP (senescence-associated secretory phenotype) — inflammatory cytokines, matrix metalloproteinases, and growth factors that drive tissue dysfunction. By clearing senescent cells, D+Q reduces SASP-driven chronic inflammation.
Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing).
Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion.
Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess).
Semaglutide is a GLP-1 receptor agonist with 94% structural homology to native GLP-1, modified with amino acid substitutions and a C-18 fatty acid chain that enables albumin binding, extending half-life to approximately 7 days. Centrally, it activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons in the arcuate nucleus of the hypothalamus, reducing hunger and increasing satiety. Peripherally, it slows gastric emptying, enhances glucose-dependent insulin secretion from pancreatic beta-cells, and reduces glucagon secretion, providing comprehensive metabolic regulation.
Research indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily.
SC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications.
Long-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials).
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →